Two DLBCL-NOS cell lines (GR, HBL1) and six HGBCL-DH cell lines (MZ, TMD8, OCI-LY10, OCI-LY9, RC, and MCA) were kind gifts from MD Anderson Cancer Center Laboratory (Drs. Pham and Ford; refs. 34 (link)–36 (link)). We performed targeted next-generation sequencing, IHC, and FISH to determine the TP53, MYC, and BCL2 alteration status in all DLBCL cell lines. Cells were cultured in RPMI1640 (CORNING) supplemented with 10% to 15% FBS (Gibco, Life Technologies) with 100 U/mL penicillin and 100 μg/mL streptomycin at 37°C in a humidified atmosphere with 5% CO2. All cultured cell lines were routinely tested for Mycoplasma spp. using a MycoSEQ Mycoplasma Detection kit (Invitrogen). Stocks of authenticated cell lines were cryopreserved, and all cell lines used here were obtained from these authenticated stocks and passaged for <6 months in culture for the performed experiments. INCB057643 and DS3032b were supported separately by Incyte and Daiichi Sankyo under approved material transfer agreement. Venetoclax (ABT-199) was purchased from Selleckchem.